The HCV revolution did not happen overnight

ACS Medicinal Chemistry Letters

Volumn 5, Issue 3, 2014, Pages 214-220

  Kwong, Ann D ^a  

^a InnovaTID   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 267; ABT 333; ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; LEPIDIPASVIR; PEGINTERFERON; POLYMERASE NUCLEOTIDE INHIBITOR; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; CANCER MORTALITY; CLINICAL PHARMACOLOGY; CRYSTAL STRUCTURE; DECOMPENSATED LIVER CIRRHOSIS; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INVESTMENT; LICENSING; LIVER CANCER; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; TREATMENT DURATION; VIRUS REPLICATION;

EID: 84896362785     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500070q     Document Type: Article

References (9)

1. Clayden, P., Collins, S., Daniels, C., Frick, M., Harrington, M., Horn, T., Jefferys, R., Kaplan, K., Lessem, E., and Swan, T., 2013 Pipeline Report. In HIV, Hepatitis C (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a Cure, and Immune-based and GeneTherapies in Development; Benzacar, A., Ed.; HIV i-Base and Treatment Action Group: New York, 2013; p 295. http://www.pipelinereport.org (accessed January 29, 2014).
2. Zalesak, M.; Francis, K.; Gedeon, A.; Gillis, J.; Hvidsten, K.; Kidder, P.; Li, H.; Martyn, D.; Orne, L.; Smith, A.; Kwong, A. Current and future disease progression of the chronic HCV population in the United States PloS One 2013, 8 (5) e63959
3. Hunt, D.; Pockros, P. What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals? Curr. Gastroenterol. Rep. 2013, 15 (1) 303
4. Lohmann, V.; Korner, F.; Koch, J.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999, 285 (5424) 110-3
5. Gao, M.; Nettles, R. E.; Belema, M.; Snyder, L. B.; Nguyen, V. N.; Fridell, R. A.; Serrano-Wu, M. H.; Langley, D. R.; Sun, J. H.; O'Boyle, D. R., II; Lemm, J. A.; Wang, C.; Knipe, J. O.; Chien, C.; Colonno, R. J.; Grasela, D. M.; Meanwell, N. A.; Hamann, L. G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 2010, 465 (7294) 96-100
6. Flexner, C. HIV drug development: the next 25 years Nat. Rev. Drug Discovery 2007, 6 (12) 959-66
7. Forum for Collaborative HIV Research. HCV Drug DevelopmentAdvisory Group. http://www.hivforum.org/projects/hcv-drug-development-advisory-group.
8. Jacobson, I. M.; Pawlotsky, J. M.; Afdhal, N. H.; Dusheiko, G. M.; Forns, X.; Jensen, D. M.; Poordad, F.; Schulz, J. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C J. Viral Hepatitis 2012, 19 (Suppl 2) 1-26
9. Dorato, M. A.; Buckley, L. A. Toxicology Testing in Drug Discovery and Development. In Current Protocols in Toxicology; Wiley: New York, 2007; Chapter 19, Unit 19.1.